Delcath Systems, Inc. (DCTH)
DCTHNASDAQ-CMMedical/Dental Instruments
$20.22
-0.3300 (-1.61%) today
Regular session, Nov 16, 12:48 PM ET
- Market cap
- $703.41m
- P/E
- 126.4
- EPS, last 4 quarters
- $0.1600
- Dividend yield
- –
- Day range
- $19.82 to $20.68
- 52-week range
- $8.12 to $22.51
- Average volume
- –
- Previous close
- $20.55
Analysts
4 coveringStrong Buy4 buy, 0 hold, 0 sell
Targets a year out average $28.75, +42.2% from here
Earnings
next estimate $-0.1000Next report
Dec 2025
+16.7%
Mar 2026
-200.0%
Jun 2026
+143.8%
Sep 2026
+270.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $20.73m | $24.99m | $29.13m | $35.10m |
| Gross profit | $17.72m | $21.26m | $26.15m | $31.18m |
| Operating income | -$2.18m | -$1.64m | $2.40m | $7.12m |
| Net income | -$1.90m | -$1.07m | $2.67m | $6.95m |
Last four quarters: revenue $109.96m, margin 6.0%, free cash flow $20.11m
News
8 latest- Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable Zacks · 3 days ago
- Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy?Zacks · 4 days ago
- Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 27.7%: Read This Before Placing a BetZacks · 4 days ago
- Healthcare Stocks Rally: EDSA And DCTH Jump 30%, VIR And IMVT Also Gain RTTNews · 7 days ago
- Delcath Systems Reports Third Quarter 2026 Results and Increases 2026 Revenue Guidance to a Range of $115 million to $117 millionFintel · 7 days ago
- Delcath (DCTH) Q3 2026 Earnings Call TranscriptThe Motley Fool · 7 days ago
- Delcath Systems Q3 Earnings Call HighlightsMarketBeat · Nov 9, 2026
- Delcath Systems Inc. Q3 Income Rises RTTNews · Nov 9, 2026
The company
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System (HDS) for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary HDS. The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- delcath.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.